Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Meghan, Bergeron"'
Autor:
Joan How, Siyang Ren, Jennifer Lombardi‐Story, Meghan Bergeron, Julia Foster, Phillip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno Hock, Anna Khachatryan, Hiroto Kikuchi, Mei Rosa Ng, Jenna Moran, Rupa Narayan, Donna Neuberg, Aura Ramos, Tina Som, Meghan Vartanian, Yi‐Bin Chen, Dan G. Duda, Gabriela S. Hobbs
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 434-442 (2022)
Abstract We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid neoplasms. We enrolled 16 patients with relapsed/refractory
Externí odkaz:
https://doaj.org/article/b768134a01424428b03dc52b7afb2c56
Autor:
Philip, Amrein, Karen, Ballen, Kristen, Stevenson, Andrew, Brunner, Gabriela, Hobbs, Hanno, Hock, Steven, McAfee, Jenna, Moran, Meghan, Bergeron, Julia, Foster, Christina, Bertoli, Kristin, McGreggor, Molly, Macrea, Meghan, Burke, Tanya, Behnam, Tina, Som, Aura, Ramos, Megan, Vartanian, Jennifer, Lombardi Story, Christine, Connolly, Traci, Blonquist, Donna, Neuberg, Amir, Fathi
Publikováno v:
Leukemia & Lymphoma. 63:1428-1435
We sought to assess the safety of adding ixazomib, an oral proteasome inhibitor, to a multi-agent treatment regimen for older adults with acute lymphoblastic leukemia (ALL). Patients 51 to 75 years of age with newly diagnosed ALL were screened. Induc
Autor:
Amir T. Fathi, Seth A. Wander, Traci M. Blonquist, Andrew M. Brunner, Philip C. Amrein, Jeffrey Supko, Nicole M. Hermance, Amity L. Manning, Hossein Sadrzadeh, Karen K. Ballen, Eyal C. Attar, Timothy A. Graubert, Gabriela Hobbs, Christelle Joseph, Ashley M. Perry, Meghan Burke, Regina Silver, Julia Foster, Meghan Bergeron, Aura Y. Ramos, Tina T. Som, Kaitlyn M. Fishman, Kristin L. McGregor, Christine Connolly, Donna S. Neuberg, Yi-Bin Chen
Publikováno v:
Haematologica, Vol 102, Iss 4 (2017)
Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase inhibitor, has demonstrated efficacy as monotherapy in trials of myeloid malignancy, and this ef
Externí odkaz:
https://doaj.org/article/3505135afba4471f95cb8a4b2bb74035
Autor:
Jenna A. Moran, Philip C. Amrein, Chrisa Hunnewell, Amir T. Fathi, Meghan Bergeron, Timothy A. Graubert, Valentina Nardi, Julia Foster, Andrew M. Brunner, Keagan S Casey, Maristela L. Onozato, Vinayak Venkataraman, Steven L. McAfee, Matthew J. Frigault, Gabriela S. Hobbs, Hanno Hock, Paola Dal Cin
Publikováno v:
Leukemia. 34:3050-3054
Autor:
Rupa Narayan, Robert P. Hasserjian, Margaret C. Wey, Tanya T. Behnan, Meghan Bergeron, Jessica Rae, Mason L. Mann, Ashkan Emadi, Christina Bertoli, Eyal C. Attar, Traci M. Blonquist, Christopher Lescinskas, Jenna A. Moran, Yi-Bin Chen, Steven L. McAfee, Vu H. Duong, Patricia Lesho, Timothy A. Graubert, Jennifer Lombardi Story, Andrew M. Brunner, Meghan Burke, Megan K. Vartanian, Gabriela S. Hobbs, Tina T. Som, Donna Neuberg, Hanno Hock, Molly Macrae, Julia Foster, Kristin McGregor, Philip C. Amrein, Amir T. Fathi, Karen K. Ballen, Frederic I. Preffer, Aura Y. Ramos, Christine Connolly
Publikováno v:
Cancer. 126:1264-1273
Background Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high interest. Brentuximab vedotin (BV) is an antibody-drug conjugate that is specific for human
Autor:
Tina T. Som, Malgorzata McMasters, Philip C. Amrein, Kaitlyn M. Fishman, Daniela Hernandez, Gabriela S. Hobbs, Andrew M. Brunner, Robin Joyce, Kristin McGregor, Karen K. Ballen, Meghan Bergeron, Donna Neuberg, Traci M. Blonquist, Jessica Rae, Ashley M. Perry, David Avigan, Tanya T. Behnan, Mark J. Levis, Jenna A. Moran, Amir T. Fathi, Meghan Burke, Christine Connolly, Aura Y. Ramos, Christelle Joseph, Julia Foster, Emma Logan
Publikováno v:
Cancer. 124:306-314
BACKGROUND Cabozantinib, a tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is approved for use in multiple malignancies. We assessed the safety and tolerability of caboza
Autor:
Jenna A. Moran, Catherine C. Smith, Rupa Narayan, Koichi Takahashi, Meghan Bergeron, Amir T. Fathi, Alexander E. Perl, Courtney D. DiNardo, Andrew M. Brunner, Mark J. Levis, Hanno Hock, Philip C. Amrein, Julia Foster, Gabriela S. Hobbs, Naval Daver
Publikováno v:
Blood. 136:11-12
Characterization of pathogenic alterations in acute myeloid leukemia (AML) has led to development of promising targeted therapies, including FLT3 (FLT3i) and IDH1/2 inhibitors (IDHi), with several approved for use; midostaurin (MIDO), gilteritinib, e
Autor:
Philip C. Amrein, Karen K. Ballen, Kristen E. Stevenson, Traci M. Blonquist, Andrew M. Brunner, Gabriela S. Hobbs, Hanno R. Hock, Steven L. McAfee, Jenna A. Moran, Meghan Bergeron, Julia E. Foster, Christina Bertoli, Kristin McGregor, Molly Macrae, Meghan Burke, Tanya T. Behnan, Tina T. Som, Aura Y. Ramos, Megan K. Vartanian, Jennifer Lombardi Story, Christine Connolly, Timothy A. Graubert, Donna S. Neuberg, Amir T. Fathi
Publikováno v:
Blood. 136:41-42
Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients >60 years of age with acute lymphoblastic leukemia (ALL) is poor with complete remission rates (CR) of approximately 60% and 3-year survivals
Autor:
Julia Foster, Rupa Narayan, Meghan Bergeron, Hanno Hock, Amir T. Fathi, Aura Y. Ramos, Philip C. Amrein, Andrew M. Brunner, Siyang Ren, Jennifer Lombardi Story, Tina T. Som, Donna Neuberg, Yi-Bin Chen, Megan K. Vartanian, Jenna A. Moran, Gabriela S. Hobbs, Chi-Joan How
Publikováno v:
Blood. 136:5-6
BACKGROUND: Angiogenesis is increasingly known to play a role in pathogenesis of hematologic malignancies, including myeloid neoplasms. Regorafenib is a multikinase inhibitor that targets angiogenic, stromal and oncogenic kinases including VEGF- 1, 2
Autor:
Donna Neuberg, Rupa Narayan, Amir T. Fathi, Aura Y. Ramos, Julia Foster, Jenna A. Moran, Traci M. Blonquist, Meghan Bergeron, Philip C. Amrein, Eyal C. Attar, Megan K. Vartanian, Molly Macrae, Christina Bertoli, Geoffrey Fell, Steven L. McAfee, Gabriela S. Hobbs, Hanno Hock, Andrew M. Brunner, Tina T. Som, Meghan Burke, Kristin McGregor, Tanya T. Behnan, Jennifer Lombardi Story
Publikováno v:
Blood. 136:7-8
Introduction: Outcomes for acute myeloid leukemia (AML) among older patients has remained largely unchanged for decades. Long-term survival for patients aged >60 years is poor (median survival 10.5 months). Targeting the proteasome in AML is attracti